Compare Illumina, Inc. (ILMN) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs PepsiCo, Inc. — how do they compare? Illumina, Inc. trades at $189.68 (market cap $27.94B), while PepsiCo, Inc. trades at $134.56 (market cap $184.89B). The key difference: PepsiCo, Inc. is far larger — about 6.6× Illumina, Inc.'s market cap, and PepsiCo, Inc. pays a 4.37% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | PEP | |
|---|---|---|
Market Cap | $27.94B | $184.89B |
Sector | Health | Consumer Staples |
52-Week High | $194.33 | $170.44 |
52-Week Low | $91.00 | $135.40 |
Enterprise Value | $29.33B | $227.39B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
PepsiCo (PEP) trades at $134.62, down 1.82% over the past day, with a bearish technical signal from moving averages. The company reported revenue of $93.93B in 2025, with a net income margin of 10.78% and a P/E ratio of 17.75. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while Q3 2026 earnings are anticipated at $2.32 EPS. Analyst consensus is a 'Hold' with a $158.50 price target, suggesting moderate upside from current levels.
The outlook for PEP hinges on execution of its North American turnaround and margin expansion initiatives. Risks include competitive pressures and sensitivity to consumer spending. With strong cash flow generation and a dividend yield near 4%, the stock offers value for income-focused investors, though near-term volatility may persist amid earnings uncertainty and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
